de Oliveira Lisboa Mateus, Brofman Paulo Roberto Slud, Schmid-Braz Ana Teresa, Rangel-Pozzo Aline, Mai Sabine
Core for Cell Technology, School of Medicine, Pontifícia Universidade Católica do Paraná-PUCPR, Curitiba 80215-901, Paraná, Brazil.
Hospital das Clínicas, Universidade Federal do Paraná, Curitiba 80060-240, Paraná, Brazil.
Cancers (Basel). 2021 May 28;13(11):2655. doi: 10.3390/cancers13112655.
Chromosomal instability (CIN), the increasing rate in which cells acquire new chromosomal alterations, is one of the hallmarks of cancer. Many studies highlighted CIN as an important mechanism in the origin, progression, and relapse of acute myeloid leukemia (AML). The ambivalent feature of CIN as a cancer-promoting or cancer-suppressing mechanism might explain the prognostic variability. The latter, however, is described in very few studies. This review highlights the important CIN mechanisms in AML, showing that CIN signatures can occur largely in all the three major AML types (de novo AML, secondary-AML, and therapy-related-AML). CIN features in AML could also be age-related and reflect the heterogeneity of the disease. Although most of these abnormalities show an adverse prognostic value, they also offer a strong new perspective on personalized therapy approaches, which goes beyond assessing CIN in vitro in patient tumor samples to predict prognosis. Current and emerging AML therapies are exploring CIN to improve AML treatment, which includes blocking CIN or increasing CIN beyond the limit threshold to induce cell death. We argue that the characterization of CIN features, not included yet in the routine diagnostic of AML patients, might provide a better stratification of patients and be extended to a more personalized therapeutic approach.
染色体不稳定(CIN),即细胞获得新的染色体改变的速率增加,是癌症的标志之一。许多研究强调CIN是急性髓系白血病(AML)发生、进展和复发的重要机制。CIN作为一种促进癌症或抑制癌症的机制所具有的矛盾特性可能解释了预后的变异性。然而,关于后者的研究非常少。本综述强调了AML中重要的CIN机制,表明CIN特征在所有三种主要的AML类型(初发AML、继发性AML和治疗相关AML)中大多都会出现。AML中的CIN特征也可能与年龄相关,并反映了该疾病的异质性。尽管这些异常大多显示出不良的预后价值,但它们也为个性化治疗方法提供了一个强有力的新视角,这超越了在患者肿瘤样本中进行体外CIN评估以预测预后的范畴。当前和新兴的AML治疗方法正在探索CIN以改善AML治疗,这包括阻断CIN或使CIN增加超过极限阈值以诱导细胞死亡。我们认为,尚未纳入AML患者常规诊断中的CIN特征的表征可能会为患者提供更好的分层,并扩展到更个性化的治疗方法。